Core Insights - Inventiva has made significant progress in its clinical program and financial position during the first half of 2025, particularly in its Phase 3 clinical trial for MASH [2][23] - The company reported revenues of €4.5 million for the first half of 2025, a substantial increase from €41,000 in the same period of 2024 [4][11] - A net loss of €175.9 million was recorded for the first half of 2025, compared to a net loss of €49.0 million in the first half of 2024 [11][12] Financial Performance - Revenues for the first half of 2025 were primarily driven by a €10 million milestone payment from Chia Tai Tianqing Pharmaceutical Group and €5 million in credit notes under a license agreement [5] - Other income decreased to €1.2 million in the first half of 2025 from €2.7 million in the same period of 2024, attributed to changes in R&D tax credit eligibility [6] - Research and development expenses were €44.9 million, down 4% from €46.8 million in the first half of 2024, reflecting a decrease in costs related to discontinued preclinical programs [7] Cash Position - As of June 30, 2025, cash and cash equivalents totaled €146.7 million, including €24.6 million in short-term deposits, with a cash runway projected until the end of Q3 2026 [8][16] - The company generated €104.8 million from financing activities in the first half of 2025, primarily from the second tranche of structured financing [14] Corporate Developments - A leadership transition occurred with the appointment of Jason Campagna as President of R&D and Chief Medical Officer [18] - The company received authorization for a workforce reduction plan, which began implementation in May 2025 [18] - The completion of enrollment for the pivotal Phase 3 clinical trial, NATiV3, was announced on April 1, 2025 [18] Future Outlook - Topline results from the NATiV3 trial are expected in the second half of 2026 [20] - The company plans to raise additional funds for long-term objectives, including potential public offerings or strategic partnerships [17]

Group 1 - Inventiva S.A. is set to release its earnings results for the first half of the year on September 29, with analysts expecting a loss of 41 cents per share [1] - The company projects quarterly revenue of $5.31 million [1] - Shares of Inventiva rose by 0.7% to close at $6.05 on the preceding Friday [1] Group 2 - HC Wainwright & Co. analyst Ananda Ghosh has a Buy rating with a price target of $20 [7] - Guggenheim analyst Etzer Darout maintained a Buy rating and increased the price target from $9 to $13 [7] - Piper Sandler analyst Yasmeen Rahimi initiated coverage with an Overweight rating and a price target of $26 [7] - Stifel analyst Annabel Samimy maintained a Buy rating but reduced the price target from $20 to $17 [7] - UBS analyst Eliana Merle initiated coverage with a Neutral rating and a price target of $3 [7]

Group 1 - Inventiva S.A. is set to release its earnings results for the first half of the year on September 29, with analysts expecting a loss of 41 cents per share and projected quarterly revenue of $5.31 million [1] - The company will host an Analyst and Investor Event on October 8 [1] - Shares of Inventiva increased by 0.7% to close at $6.05 on the preceding Friday [1] Group 2 - HC Wainwright & Co. analyst Ananda Ghosh has a Buy rating on the stock with a price target of $20, initiated on September 3, 2025 [7] - Guggenheim analyst Etzer Darout maintained a Buy rating and raised the price target from $9 to $13 on September 2, 2025 [7] - Piper Sandler analyst Yasmeen Rahimi initiated coverage with an Overweight rating and a price target of $26 on August 27, 2025 [7] - Stifel analyst Annabel Samimy maintained a Buy rating but reduced the price target from $20 to $17 on November 22, 2024 [7] - UBS analyst Eliana Merle initiated coverage with a Neutral rating and a price target of $3 on November 12, 2024 [7]

Core Viewpoint - Inventiva S.A. (IVA) has shown a downtrend recently, losing 5.4% over the past four weeks, but a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottom formation, suggesting that selling pressure may be exhausting and that bulls could be gaining control [2][5]. - A hammer pattern forms when there is a small candle body with a long lower wick, indicating that the stock opened lower, made a new low, but closed near or above the opening price, signaling potential support [4][5]. - This pattern can occur across various timeframes and is utilized by both short-term and long-term investors [5]. Fundamental Analysis - There has been a positive trend in earnings estimate revisions for IVA, which is a bullish indicator suggesting potential price appreciation [7]. - The consensus EPS estimate for the current year has increased by 4.4% over the last 30 days, indicating that analysts expect better earnings than previously predicted [8]. - IVA holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10].

Core Viewpoint - Inventiva is hosting an analyst and investor event to provide a strategic update ahead of the anticipated Phase 3 topline results for lanifibranor, its lead asset for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) [1] Company Overview - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for MASH [3] - The company is evaluating lanifibranor, a novel pan-PPAR agonist, in the pivotal Phase 3 NATiV3 clinical trial for adult patients with MASH, a progressive chronic liver disease [3] Event Details - The event will take place on October 8, 2025, from 11:30 am to 2:00 pm ET in New York City, with a live webcast available [1] - The program will include presentations from Inventiva's leadership and insights from key opinion leaders in the MASH field, along with a patient representative [2][5] Key Topics of Discussion - An update on lanifibranor ahead of the anticipated Phase 3 NATiV3 topline results expected in the second half of 2026 [5] - A deep dive into lanifibranor's mechanism of action and clinical evidence, including findings from the Phase 2b trial [6] - Discussion on the design and objectives of the ongoing Phase 3 study, including patient baseline characteristics [6] - Insights from renowned experts in the field, including Dr. Nezam Afdhal, Dr. William Alazawi, Henry E. Chang, and Dr. Arun Sanyal [6]

U.S. stock futures were mixed this morning, with the Dow futures falling around 100 points on Friday.Shares of RH RH fell sharply in pre-market trading after the company posted weaker-than-expected second-quarter results after Thursday's closing bell.RH reported quarterly earnings of $2.93 per share, which fell short of the analyst estimate of $3.20. Quarterly revenue came in at $899.15 million, which missed the Street estimate of $904.64 million.RH shares dipped 11.5% to $201.98 in the pre-market trading s ...

Company Overview - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical needs [2][4] - The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for treating adult patients with MASH, a common and progressive chronic liver disease [2] Upcoming Investor Events - The company will participate in several upcoming investor events, including: - H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 3:00 PM EDT in New York, NY [1] - 8th Edition of the Lyon Pôle Bourse Forum on September 23, 2025, in Lyon, France [1] - KBC Life Sciences Conference on September 25, 2025, at 5:00 AM EDT in Brussels, Belgium [2] - Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025, at 9:30 AM EDT, virtually [2] - European MIDCAP Event 2025 from September 30 to October 1, 2025, in Paris, France [2]

Core Insights - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) [1][3] - The company will participate in the Canaccord Genuity 45th Annual Growth Conference, highlighting updates on lanifibranor and the Phase III NATiV3 trial [2][3] Company Overview - Inventiva is listed on Euronext Paris and NASDAQ, focusing on oral small molecule therapies for MASH and other diseases with significant unmet medical needs [3][4] - The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in a pivotal Phase 3 clinical trial for adult patients with MASH [3]

Core Points - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical needs [1][6] - The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for treating adult patients with MASH [6] Financial Summary - As of June 30, 2025, the liquidity account had cash resources of €428,212.57, with a total of 84,532 shares available [3] - The number of executions on the buy side for the semester was 1,642, with a traded volume of 267,584 shares for €744,692.94, while the sell side had 1,878 executions and a traded volume of 296,504 shares for €819,771.51 [3] - The previous half-year report as of December 31, 2024, indicated cash resources of €349,630.55 and 113,452 shares available [3] Trading Activity - The trading activity for the buy side included various dates with notable volumes, such as 2,741 shares traded for €5,865.74 on February 1, 2025, and 2,000 shares for €4,580.00 on February 10, 2025 [2][4] - The sell side also showed significant activity, with 14,338 shares traded for €34,267.82 on January 23, 2025, and 9,521 shares for €26,373.17 on February 24, 2025 [2][4] Company Overview - Inventiva is publicly listed on Euronext Paris and Nasdaq Global Market, indicating its presence in both European and American markets [7] - The company aims to address significant unmet medical needs through its innovative therapies, particularly focusing on chronic liver diseases [6]

Core Viewpoint - Inventiva reported preliminary financial results for the first half of 2025, highlighting significant changes in cash position, operating expenses, and revenue generation, as well as the need for future funding to support its clinical development efforts [1][10]. Financial Position - As of June 30, 2025, the company's cash and cash equivalents were €122.1 million, with an additional €24.6 million in short-term deposits, an increase from €96.6 million at the end of 2024 [2][13]. - The net cash used in operating activities was (€53.9) million in H1 2025, compared to (€48.3) million in H1 2024, primarily due to working capital changes and pipeline prioritization [3]. - Net cash used in investing activities was (€24.8) million in H1 2025, a significant decrease from €8.9 million generated in H1 2024, attributed to new deposit subscriptions [4]. - Financing activities generated €104.9 million in H1 2025, a substantial increase from €22.6 million in H1 2024, mainly from the second tranche of structured financing [5]. Revenue Generation - Revenues for the first half of 2025 amounted to €4.5 million, a notable increase from zero in the same period of 2024 [10]. - The revenue included a €10 million milestone payment from CTTQ and €5 million in credit notes under a license agreement with CTTQ [11]. Future Outlook - The company estimates that its current cash position, combined with the expected milestone payment from CTTQ, will fund operations until the end of Q3 2026 [7]. - Additional funding will be necessary for long-term objectives related to the development and commercialization of lanifibranor, potentially through public offerings, private placements, or strategic partnerships [8].